Related references
Note: Only part of the references are listed.A review of the therapeutic management of ulcerative colitis
Nasar Aslam et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2022)
Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease: Limits and improvements
Jose Maria Giraldez-Montero et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits
Emilio J. Laserna-Mendieta et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2021)
Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients
Sonia Facchin et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)
Infliximab trough levels: A comparison between the Quantum Blue Infliximab assay and the established ELISA
Ming Han Lim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2020)
Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies
Konstantinos H. Katsanos et al.
CLINICAL IMMUNOLOGY (2019)
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease
Debora Curci et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2019)
Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels
Vasilije Novakovic et al.
CLINICAL BIOCHEMISTRY (2019)
Accuracy of the new rapid test for monitoring adalimumab levels
Catia Rocha et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2019)
Letter: new thresholds need to be defined when using point of care assays to monitor infliximab trough levels in IBD patients
D. Dutzer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease
Amy Hemperly et al.
CLINICAL PHARMACOKINETICS (2018)
Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis
Amanda Ricciuto et al.
JOURNAL OF CROHNS & COLITIS (2018)
American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases
Niels Vande Casteele et al.
GASTROENTEROLOGY (2017)
A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease
Johannan F. Brandse et al.
INFLAMMATORY BOWEL DISEASES (2017)
Clinical performance of an infliximab rapid quantification assay
Fernando Magro et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2017)
Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases
N. Mitrev et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Targeting TNF-α for the treatment of inflammatory bowel disease
Thomas Billiet et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial
Casper Steenholdt et al.
GUT (2014)
The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
Bella Ungar et al.
GUT (2014)
Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study
Iris Dotan et al.
INFLAMMATORY BOWEL DISEASES (2014)
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Daniel Tracey et al.
PHARMACOLOGY & THERAPEUTICS (2008)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
